RF&L Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

RF&L Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-48,000	Closed	-$146K	–	60
2024 Q4	$146K	Hold	48,000	–	–	0.1%	57
2024 Q3	$249K	Hold	48,000	–	–	0.18%	54
2024 Q2	$123K	Buy	48,000 +15,000	+45%	+$51.2K	0.09%	56
2024 Q1	$162K	Hold	33,000	–	–	0.13%	56
2023 Q4	$290K	Buy	33,000 +5,000	+18%	+$41K	0.24%	49
2023 Q3	$321K	Buy	28,000 +8,000	+40%	+$154K	0.3%	43
2023 Q2	$506K	Hold	20,000	–	–	0.46%	36
2023 Q1	$644K	Buy	+20,000	New	+$623K	0.62%	34

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RF&L Wealth Management's RVNC Position: Q1 2025 in Review

RF&L Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 48,000 shares — an estimated $146K sold.

RF&L Wealth Management first reported a position in RVNC in Q1 2023 and held it in 8 quarters. The position peaked at $644K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

RF&L Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
RF&L Wealth Management sold 48,000 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $146K.
RF&L Wealth Management first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 8 quarters.
RF&L Wealth Management's Revance Therapeutics, Inc. position peaked at $644K in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on RF&L Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.